v1
Tolerance, safety, and kinetics of the new antineoplastic compound dexniguldipine-HCl after oral administration: a phase I dose-escalation trial.
Identifier:nobleid.org/w1/20260515/FD5FDA16
Type:Journal Article
0 views
Embeddable Badge
[](https://nobleid.org/work/w1/20260515/FD5FDA16)
Bibliometric Analysis
Impact metrics, research fronts, co-authorship networks →
Authors & Claims